questionsmedicales.fr
Cellules
Cellules cultivées
Cellules cancéreuses en culture
Lignée cellulaire tumorale
Cellules THP-1
Cellules THP-1 : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Lignées cellulaires
Monocytes
Cytométrie en flux
Immunofluorescence
Contamination cellulaire
Mycoplasmes
Sensibilité aux médicaments
Pharmacologie
Symptômes
5
Marqueurs cellulaires
Activation cellulaire
Différenciation cellulaire
Macrophages
Prévention
5
Prévention de la contamination
Techniques aseptiques
Conditions de culture
Milieu de culture
Soins cellulaires
Stress cellulaire
Viabilité cellulaire
Congélation
Cryogénisation
Conservation cellulaire
Traitements
5
Recherche biomédicale
Médicaments
Modification génétique
CRISPR
Traitements anti-inflammatoires
Anticancéreux
Toxicité
Composés chimiques
Modélisation des maladies
Maladies inflammatoires
Complications
5
Complications expérimentales
Biais
Réponses immunitaires
Immunité
Risques de laboratoire
Contamination croisée
Agents externes
Fonction cellulaire
Minimisation des risques
Contrôles de qualité
Facteurs de risque
5
Facteurs de croissance
Milieu de culture
Agents environnementaux
Sensibilité cellulaire
Stress oxydatif
Viabilité cellulaire
Facteurs génétiques
Réponse immunitaire
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Cellules THP-1 : Questions médicales les plus fréquentes",
"headline": "Cellules THP-1 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Cellules THP-1 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-26",
"dateModified": "2025-03-21",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Cellules THP-1"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Lignée cellulaire tumorale",
"url": "https://questionsmedicales.fr/mesh/D045744",
"about": {
"@type": "MedicalCondition",
"name": "Lignée cellulaire tumorale",
"code": {
"@type": "MedicalCode",
"code": "D045744",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "A11.251.860.180"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Cellules THP-1",
"alternateName": "THP-1 Cells",
"code": {
"@type": "MedicalCode",
"code": "D000074084",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Terumasa Ikeda",
"url": "https://questionsmedicales.fr/author/Terumasa%20Ikeda",
"affiliation": {
"@type": "Organization",
"name": "2 Institute for Molecular Virology, Minneapolis, MN 55455, USA."
}
},
{
"@type": "Person",
"name": "Michael A Carpenter",
"url": "https://questionsmedicales.fr/author/Michael%20A%20Carpenter",
"affiliation": {
"@type": "Organization",
"name": "3 Center for Genome Engineering, Minneapolis, MN 55455, USA."
}
},
{
"@type": "Person",
"name": "William L Brown",
"url": "https://questionsmedicales.fr/author/William%20L%20Brown",
"affiliation": {
"@type": "Organization",
"name": "4 Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA."
}
},
{
"@type": "Person",
"name": "Reuben S Harris",
"url": "https://questionsmedicales.fr/author/Reuben%20S%20Harris",
"affiliation": {
"@type": "Organization",
"name": "3 Center for Genome Engineering, Minneapolis, MN 55455, USA."
}
},
{
"@type": "Person",
"name": "Valentina Galbiati",
"url": "https://questionsmedicales.fr/author/Valentina%20Galbiati",
"affiliation": {
"@type": "Organization",
"name": "Università Degli Studi di Milano, Laboratory of Toxicology, Dipartimento di Scienze Politiche ed Ambientali, Milan, Italy."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Radiographic Contrast Media and the Kidney.",
"datePublished": "2022-07-01",
"url": "https://questionsmedicales.fr/article/35777831",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2215/CJN.16311221"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Contrast Media Toxicity and Its Prevention].",
"datePublished": "2023-10-26",
"url": "https://questionsmedicales.fr/article/38010244",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": null
}
},
{
"@type": "ScholarlyArticle",
"name": "Contrast media volume reduction with the DyeVert",
"datePublished": "2023-09-05",
"url": "https://questionsmedicales.fr/article/37668067",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/ccd.30809"
}
},
{
"@type": "ScholarlyArticle",
"name": "Iodinated Contrast Media Conservation Measures During a Global Shortage: Effect on Contrast Media Use at a Large Health System.",
"datePublished": "2022-06-22",
"url": "https://questionsmedicales.fr/article/35731095",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2214/AJR.22.28080"
}
},
{
"@type": "ScholarlyArticle",
"name": "Strategies for calculating contrast media dose for chest CT.",
"datePublished": "2023-06-12",
"url": "https://questionsmedicales.fr/article/37303003",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s41747-023-00345-w"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Cellules",
"item": "https://questionsmedicales.fr/mesh/D002477"
},
{
"@type": "ListItem",
"position": 3,
"name": "Cellules cultivées",
"item": "https://questionsmedicales.fr/mesh/D002478"
},
{
"@type": "ListItem",
"position": 4,
"name": "Cellules cancéreuses en culture",
"item": "https://questionsmedicales.fr/mesh/D014407"
},
{
"@type": "ListItem",
"position": 5,
"name": "Lignée cellulaire tumorale",
"item": "https://questionsmedicales.fr/mesh/D045744"
},
{
"@type": "ListItem",
"position": 6,
"name": "Cellules THP-1",
"item": "https://questionsmedicales.fr/mesh/D000074084"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Cellules THP-1 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Cellules THP-1",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-05",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Cellules THP-1",
"description": "Comment identifier les cellules THP-1 en laboratoire ?\nQuels tests sont utilisés pour caractériser les cellules THP-1 ?\nLes cellules THP-1 peuvent-elles être contaminées ?\nQuelle est la source des cellules THP-1 ?\nLes cellules THP-1 sont-elles sensibles à des médicaments ?",
"url": "https://questionsmedicales.fr/mesh/D000074084?mesh_terms=Contrast+Media#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Cellules THP-1",
"description": "Quels sont les marqueurs d'activation des cellules THP-1 ?\nLes cellules THP-1 montrent-elles des signes d'inflammation ?\nComment les cellules THP-1 réagissent-elles aux pathogènes ?\nLes cellules THP-1 peuvent-elles se différencier ?\nQuels effets ont les cytokines sur les cellules THP-1 ?",
"url": "https://questionsmedicales.fr/mesh/D000074084?mesh_terms=Contrast+Media#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Cellules THP-1",
"description": "Comment prévenir la contamination des cellules THP-1 ?\nQuelles conditions de culture sont idéales pour les cellules THP-1 ?\nLes cellules THP-1 nécessitent-elles des soins particuliers ?\nComment assurer la viabilité des cellules THP-1 ?\nLes cellules THP-1 peuvent-elles être cryogénisées ?",
"url": "https://questionsmedicales.fr/mesh/D000074084?mesh_terms=Contrast+Media#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Cellules THP-1",
"description": "Comment les cellules THP-1 sont-elles utilisées en recherche ?\nPeut-on modifier génétiquement les cellules THP-1 ?\nQuels traitements sont testés sur les cellules THP-1 ?\nLes cellules THP-1 peuvent-elles être utilisées pour des tests de toxicité ?\nComment les cellules THP-1 aident-elles à comprendre les maladies ?",
"url": "https://questionsmedicales.fr/mesh/D000074084?mesh_terms=Contrast+Media#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Cellules THP-1",
"description": "Quelles complications peuvent survenir lors de l'utilisation des cellules THP-1 ?\nLes cellules THP-1 peuvent-elles induire des réponses immunitaires indésirables ?\nQuels risques sont associés à la manipulation des cellules THP-1 ?\nLes cellules THP-1 peuvent-elles être affectées par des agents externes ?\nComment minimiser les complications lors des expériences avec THP-1 ?",
"url": "https://questionsmedicales.fr/mesh/D000074084?mesh_terms=Contrast+Media#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Cellules THP-1",
"description": "Quels facteurs influencent la croissance des cellules THP-1 ?\nLes cellules THP-1 sont-elles sensibles à des agents environnementaux ?\nQuels traitements peuvent affecter les cellules THP-1 ?\nLes cellules THP-1 sont-elles affectées par le stress oxydatif ?\nQuels facteurs génétiques influencent les cellules THP-1 ?",
"url": "https://questionsmedicales.fr/mesh/D000074084?mesh_terms=Contrast+Media#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les cellules THP-1 en laboratoire ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cellules THP-1 sont identifiées par leur morphologie et leur expression de marqueurs spécifiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour caractériser les cellules THP-1 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests comme la cytométrie en flux et l'immunofluorescence sont utilisés."
}
},
{
"@type": "Question",
"name": "Les cellules THP-1 peuvent-elles être contaminées ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, comme toutes les lignées cellulaires, elles peuvent être contaminées par des bactéries ou des mycoplasmes."
}
},
{
"@type": "Question",
"name": "Quelle est la source des cellules THP-1 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cellules THP-1 proviennent de la moelle osseuse d'un patient atteint de leucémie."
}
},
{
"@type": "Question",
"name": "Les cellules THP-1 sont-elles sensibles à des médicaments ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont souvent utilisées pour tester la sensibilité à divers agents pharmacologiques."
}
},
{
"@type": "Question",
"name": "Quels sont les marqueurs d'activation des cellules THP-1 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les marqueurs incluent CD14, CD11b et CD68, indiquant leur activation."
}
},
{
"@type": "Question",
"name": "Les cellules THP-1 montrent-elles des signes d'inflammation ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles produisent des cytokines pro-inflammatoires lorsqu'elles sont activées."
}
},
{
"@type": "Question",
"name": "Comment les cellules THP-1 réagissent-elles aux pathogènes ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles phagocytent les pathogènes et sécrètent des médiateurs inflammatoires."
}
},
{
"@type": "Question",
"name": "Les cellules THP-1 peuvent-elles se différencier ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent se différencier en macrophages sous l'influence de certains facteurs."
}
},
{
"@type": "Question",
"name": "Quels effets ont les cytokines sur les cellules THP-1 ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cytokines modulent leur activation et leur capacité à produire d'autres médiateurs."
}
},
{
"@type": "Question",
"name": "Comment prévenir la contamination des cellules THP-1 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utiliser des techniques aseptiques et vérifier régulièrement la pureté cellulaire."
}
},
{
"@type": "Question",
"name": "Quelles conditions de culture sont idéales pour les cellules THP-1 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles nécessitent un milieu riche en nutriments et une température contrôlée."
}
},
{
"@type": "Question",
"name": "Les cellules THP-1 nécessitent-elles des soins particuliers ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles doivent être manipulées avec précaution pour éviter le stress cellulaire."
}
},
{
"@type": "Question",
"name": "Comment assurer la viabilité des cellules THP-1 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir des conditions optimales de culture et éviter les cycles de congélation-décongélation."
}
},
{
"@type": "Question",
"name": "Les cellules THP-1 peuvent-elles être cryogénisées ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent être cryogénisées pour une conservation à long terme."
}
},
{
"@type": "Question",
"name": "Comment les cellules THP-1 sont-elles utilisées en recherche ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont utilisées pour étudier les mécanismes immunitaires et tester des médicaments."
}
},
{
"@type": "Question",
"name": "Peut-on modifier génétiquement les cellules THP-1 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des techniques comme CRISPR peuvent être utilisées pour modifier leur génome."
}
},
{
"@type": "Question",
"name": "Quels traitements sont testés sur les cellules THP-1 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements anti-inflammatoires et anticancéreux sont souvent testés."
}
},
{
"@type": "Question",
"name": "Les cellules THP-1 peuvent-elles être utilisées pour des tests de toxicité ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont souvent utilisées pour évaluer la toxicité des composés chimiques."
}
},
{
"@type": "Question",
"name": "Comment les cellules THP-1 aident-elles à comprendre les maladies ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles modélisent des maladies inflammatoires et infectieuses pour étudier les mécanismes."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir lors de l'utilisation des cellules THP-1 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des résultats biaisés peuvent survenir si les cellules sont contaminées ou mal caractérisées."
}
},
{
"@type": "Question",
"name": "Les cellules THP-1 peuvent-elles induire des réponses immunitaires indésirables ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent parfois produire des réponses immunitaires non spécifiques."
}
},
{
"@type": "Question",
"name": "Quels risques sont associés à la manipulation des cellules THP-1 ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le risque principal est la contamination croisée avec d'autres lignées cellulaires."
}
},
{
"@type": "Question",
"name": "Les cellules THP-1 peuvent-elles être affectées par des agents externes ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des agents comme les toxines ou les médicaments peuvent altérer leur fonction."
}
},
{
"@type": "Question",
"name": "Comment minimiser les complications lors des expériences avec THP-1 ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Suivre des protocoles stricts et effectuer des contrôles réguliers de qualité."
}
},
{
"@type": "Question",
"name": "Quels facteurs influencent la croissance des cellules THP-1 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs comme la température, le pH et la composition du milieu influencent leur croissance."
}
},
{
"@type": "Question",
"name": "Les cellules THP-1 sont-elles sensibles à des agents environnementaux ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent être affectées par des agents chimiques ou physiques dans leur environnement."
}
},
{
"@type": "Question",
"name": "Quels traitements peuvent affecter les cellules THP-1 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements comme les cytokines ou les médicaments peuvent moduler leur activité."
}
},
{
"@type": "Question",
"name": "Les cellules THP-1 sont-elles affectées par le stress oxydatif ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress oxydatif peut altérer leur fonction et leur viabilité."
}
},
{
"@type": "Question",
"name": "Quels facteurs génétiques influencent les cellules THP-1 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des variations génétiques peuvent affecter leur réponse aux stimuli immunitaires."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 21/03/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
2 Institute for Molecular Virology, Minneapolis, MN 55455, USA.
3 Center for Genome Engineering, Minneapolis, MN 55455, USA.
5 Howard Hughes Medical Institute, University of Minnesota, Minneapolis, MN 55455, USA.
1 Department of Biochemistry, Molecular Biology, and Biophysics, Minneapolis, MN 55455, USA.
4 Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Publications dans "Cellules THP-1" :
3 publications dans cette catégorie
Affiliations :
3 Center for Genome Engineering, Minneapolis, MN 55455, USA.
1 Department of Biochemistry, Molecular Biology, and Biophysics, Minneapolis, MN 55455, USA.
4 Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
2 Institute for Molecular Virology, Minneapolis, MN 55455, USA.
5 Howard Hughes Medical Institute, University of Minnesota, Minneapolis, MN 55455, USA.
Publications dans "Cellules THP-1" :
3 publications dans cette catégorie
Affiliations :
4 Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
3 Center for Genome Engineering, Minneapolis, MN 55455, USA.
2 Institute for Molecular Virology, Minneapolis, MN 55455, USA.
1 Department of Biochemistry, Molecular Biology, and Biophysics, Minneapolis, MN 55455, USA.
Publications dans "Cellules THP-1" :
3 publications dans cette catégorie
Affiliations :
3 Center for Genome Engineering, Minneapolis, MN 55455, USA.
1 Department of Biochemistry, Molecular Biology, and Biophysics, Minneapolis, MN 55455, USA.
4 Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
2 Institute for Molecular Virology, Minneapolis, MN 55455, USA.
5 Howard Hughes Medical Institute, University of Minnesota, Minneapolis, MN 55455, USA.
Publications dans "Cellules THP-1" :
3 publications dans cette catégorie
Affiliations :
Università Degli Studi di Milano, Laboratory of Toxicology, Dipartimento di Scienze Politiche ed Ambientali, Milan, Italy.
Publications dans "Cellules THP-1" :
3 publications dans cette catégorie
Affiliations :
Università Degli Studi di Milano, Laboratory of Toxicology, Dipartimento di Scienze Politiche ed Ambientali, Milan, Italy.
Publications dans "Cellules THP-1" :
2 publications dans cette catégorie
Affiliations :
Key Laboratory of The Ministry of Education for Conservation and Utilization of Special Biological Resources in The West, Yinchuan, Ningxia 750021, P.R. China.
College of Life Science, Ningxia University, Yinchuan, Ningxia 750021, P.R. China.
Publications dans "Cellules THP-1" :
2 publications dans cette catégorie
Affiliations :
Key Laboratory of The Ministry of Education for Conservation and Utilization of Special Biological Resources in The West, Yinchuan, Ningxia 750021, P.R. China.
College of Life Science, Ningxia University, Yinchuan, Ningxia 750021, P.R. China.
Publications dans "Cellules THP-1" :
2 publications dans cette catégorie
Affiliations :
Key Laboratory of The Ministry of Education for Conservation and Utilization of Special Biological Resources in The West, Yinchuan, Ningxia 750021, P.R. China.
College of Life Science, Ningxia University, Yinchuan, Ningxia 750021, P.R. China.
Publications dans "Cellules THP-1" :
2 publications dans cette catégorie
Affiliations :
Key Laboratory of The Ministry of Education for Conservation and Utilization of Special Biological Resources in The West, Yinchuan, Ningxia 750021, P.R. China.
College of Life Science, Ningxia University, Yinchuan, Ningxia 750021, P.R. China.
Publications dans "Cellules THP-1" :
2 publications dans cette catégorie
Affiliations :
Key Laboratory of The Ministry of Education for Conservation and Utilization of Special Biological Resources in The West, Yinchuan, Ningxia 750021, P.R. China.
College of Life Science, Ningxia University, Yinchuan, Ningxia 750021, P.R. China.
Publications dans "Cellules THP-1" :
2 publications dans cette catégorie
Affiliations :
Cheeloo College of Medicine, Shandong University Ji'nan 250012, China.
Publications dans "Cellules THP-1" :
2 publications dans cette catégorie
Affiliations :
Università Degli Studi di Pavia, Dipartimento di Scienze del Farmaco, Pavia, Italy.
Publications dans "Cellules THP-1" :
2 publications dans cette catégorie
Affiliations :
Università Degli Studi di Pavia, Dipartimento di Scienze del Farmaco, Pavia, Italy.
Scuola Universitaria Superiore IUSS, Pavia, Italy.
Publications dans "Cellules THP-1" :
2 publications dans cette catégorie
Affiliations :
Università Degli Studi di Pavia, Dipartimento di Scienze del Farmaco, Pavia, Italy.
Publications dans "Cellules THP-1" :
2 publications dans cette catégorie
Affiliations :
Università Degli Studi di Pavia, Dipartimento di Scienze del Farmaco, Pavia, Italy.
Publications dans "Cellules THP-1" :
2 publications dans cette catégorie
Affiliations :
University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia.
Publications dans "Cellules THP-1" :
2 publications dans cette catégorie
Affiliations :
Department of Hematology, West China School of Medicine/West China Hospital, Sichuan University, Chengdu, China, 3341148215@qq.com.
Department of Hematology, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Publications dans "Cellules THP-1" :
2 publications dans cette catégorie
Affiliations :
Department of Hematology, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Publications dans "Cellules THP-1" :
2 publications dans cette catégorie
Affiliations :
Shandong Provincial Key Laboratory of Animal Resistance Biology, Institute of Biomedical Sciences, College of Life Sciences, Shandong Normal University, Jinan, Shandong 250014, P.R. China.
Publications dans "Cellules THP-1" :
AKI is a potential complication of intravascular iodinated contrast exposure. Contrast-associated AKI, which typically manifests as small and transient decrements in kidney function that develop withi...
Intravenous iodinated contrast media are commonly used in clinical practice, ranging from medical imaging to interventional radiology (IR) procedures and endovascular interventions. Compared with pati...
Contrast associated acute kidney injury (CA-AKI) can lead to an increased risk of adverse events. Contrast media (CM) volume reduction has been advocated as a pivotal strategy to prevent CA-AKI in sta...
To compare the effectiveness of CM volume reduction with the DyeVert...
We prospectively collected data from 136 patients with stable coronary artery disease at high risk of CA-AKI treated with left ventricular end diastolic pressure (LVEDP)- guided hydration and undergoi...
Patients in the DyeVert group were treated with a significant lower CM volume (median: 47.5 vs. 84.0 mL, p < 0.001). The trend in creatinine increase was lower (p = 0.004) and the Δ of creatinine (0-4...
CM volume reduction with the DyeVert...
The aim of this study was to quantify the effect of iodinated contrast media (ICM) conservation measures implemented at a single health system during a global shortage, comparing the 12-month period b...
Total body weight (TBW) is a frequently used contrast media (CM) strategy for dose calculation in enhanced CT, yet it is suboptimal as it lacks consideration of patient characteristics, such as body f...
Eighty-nine adult patients referred for CM thoracic CT were retrospectively included, categorized as either normal, muscular, or overweight. Patient body composition data was used to calculate the CM ...
BIA demonstrated the highest and lowest calculated CM dose in muscular and overweight groups respectively, compared to other strategies. For the normal group, the lowest calculated CM dose was achieve...
The BIA method is more adaptive to variations in patient body habitus especially in muscular and overweight patients and is most closely correlated to patient demographics. This study could support ut...
The BIA-based method is adaptive to variations in body habitus especially in muscular and overweight patients and is closely correlated to patient demographics for contrast-enhanced chest CT....
• Calculations based on BIA showed the largest variation in CM dose. • Lean body weight using BIA demonstrated the strongest correlation to patient demographics. • Lean body weight BIA protocol may be...
A severe shortage of iodinated contrast medium (ICM) has forced radiology departments around the world to implement strategies to reduce contrast utilization. The aim of this study was to evaluate the...
Our radiology department instituted several ICM-conserving interventions on 13...
The average daily number of CECT (all), CECT (inpatient and ED), CTPA, CECT AP, and 'Code stroke' CT scans decreased significantly (P < 0.01), by 58.6%, 68.8%, 74.1%, 88.0%, and 37.5%, respectively. T...
Interventions in CT alone, focused on improving patient triage to CECT while avoiding deferment of any outpatient oncology studies, have achieved an approximately two-thirds reduction in ICM consumpti...
To identify the risk factors for moderate and severe contrast media extravasation and provide effective guidance to reduce the degree of extravasation injuries....
We observed 224 adult patients who underwent contrast media extravasation at Xiangya Hospital of Central South University, Hunan Provincial Maternal and Child Healthcare Hospital, and Xiangya Changde ...
Among 224 patients, 0 (0%) had severe, 18 (8.0%) had moderate, and 206 (92.0%) had mild contrast media extravasation injury. Multivariate logistic regression analysis revealed malignant tumors (odds r...
Risk factors for moderate contrast media extravasation injury are malignant tumors, iohexol, large-volume (> 50 mL) extravasation, and back-of-the-hand injection. Analysis of these risk factors can he...
High-risk patients with extravasation support should choose the appropriate contrast media type, avoiding back-of-the-hand injections. We recommend that patients with cancer be implanted with a high-p...
Iodinated- (ICM) and gadolinium-based (GCM) contrast media are used in radiology imaging techniques, such as computer tomography (CT) and magnetic resonance (MR), respectively. The paper aims to analy...
To assess the role of atorvastatin to the frequency of contrast-induced acute kidney injury (CI-AKI) in patients with cardiovascular diseases (CVD) undergoing computed tomography (CT) with intravenous...
One hundred patients with CVD undergoing CT with with intravenous contrast media administration were included in prospective observational study (ClinicalTrials.gov ID NCT04666389). Patients were divi...
CI-AKI was diagnosed in 4 (3.96%) patients. At the same time, it was not possible to establish statistically significant relationships (p0.05) between risk factors and the development of CI-AKI. Stati...
Cardiovascular diseases may increase the risk of CI-AKI after computed tomography with intravenous contrast media administration. Therefore, it is recommended to evaluate the serum creatinine concentr...
To pool and summarise published data of pulmonary blood flow (PBF), pulmonary blood volume (PBV) and mean transit time (MTT) of the human lung, obtained with perfusion MRI or CT to provide reliable re...
PubMed was systematically searched to identify studies that quantified PBF/PBV/MTT in the human lung by injection of contrast agent, imaged by MRI or CT. Only data analysed by 'indicator dilution theo...
PBV was obtained from 313 measurements from 14 publications (wM: 13.97 ml/100 ml, wSD: 4.21 ml/100 ml, wCoV 0.30). MTT was obtained from 188 measurements from 10 publications (wM: 5.91 s, wSD: 1.84 s ...
Reference values for PBF, MTT and PBV were obtained in HV. The literature data are insufficient to draw strong conclusions regarding disease reference values....